Business Wire

O-RAN Announces Certification and Badging Program, Next Generation Research Group, Open RAN Summit, and Results of Spring 2022 PlugFest

30.6.2022 10:33:00 EEST | Business Wire | Press release

Share

Since its beginning in 2018, the O-RAN ALLIANCE’s mission has been transforming Radio Access Networks towards open, intelligent, virtualized and fully interoperable RAN. Now, the O-RAN Ecosystem counts more than 340 companies and institutions from all over the world. O-RAN’s emphasis on openness is reflected in its setup as an open technical organization, according to the WTO criteria, where incumbent as well as emerging industry players or academic institutions can join and contribute.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005362/en/

O-RAN ALLIANCE Industry Summit June 2022

The O-RAN ALLIANCE Industry Summit June 2022 concluded on June 29, 2022 and is now available for on-demand replay at our website.

O-RAN Certification and Badging Program in cooperation with Open Test and Integration Centres (OTIC)

O-RAN ALLIANCE has launched its Certification and Badging program. O-RAN certificates state that an equipment or function is conformant to O-RAN specifications, whereas the O-RAN badges confirm interoperability or end-to-end functionality of an O-RAN solution. O-RAN certificates and badges will be issued by the Open Testing and Integration Centers, or OTICs.

The OTICs provide collaborative, open, and impartial working environment to ensure consistency and quality of testing of O-RAN products and solutions. O-RAN ALLIANCE has just approved the 7th OTIC and first one in Americas: Kyrio O-RAN Test and Integration Lab hosted by CableLabs.

See the full list of approved OTICs at our website.

O-RAN next Generations Research Group will focus on future network standards

O-RAN ALLIANCE has formed its next Generations Research Group (nGRG).

“The nGRG will focus on research of open and intelligent RAN principles in 6G and future network standards,” said Chih-Lin I, Co-chair of O-RAN Technical Steering Committee and Chief Scientist, Wireless Technologies, China Mobile Research Institute. “We are seeing very positive uptake on nGRG from the O-RAN ecosystem as well as the academic sphere and we are looking forward to seeing further progress of the research.”

Open RAN Summit @ Fyuz to be held on 25-26 October 2022 in Madrid

O-RAN ALLIANCE is delighted to announce the Open RAN Summit @ Fyuz, powered by the O-RAN ALLIANCE and Telecom Infra Project, which will take place in Madrid on October 25-26, 2022. We welcome TIP as they join us for this combined event.

Designed to bring together stakeholders from across the ecosystem, the Open RAN Summit at Fyuz will deliver the latest from the industry as we drive towards more disaggregated, intelligent, open, and fully interoperable mobile networks. All of that, served in a unique experience combining technology with gastronomy to stir your imagination. Learn more and register at the Fyuz event website.

O-RAN Global PlugFest Spring 2022 concluded at 3 continents with 50 participants

Starting from this year, O-RAN ALLIANCE switches to hosting two global PlugFests per year, to accommodate for ever increasing interest of the diverse O-RAN community to efficiently test and integrate their O-RAN solutions.

O-RAN Global PlugFest Spring 2022 took place at 3 continents with 50 participating companies or institutions, some of which participated at more than one venue.

In North America, the O-RAN ‘PoCFest’ hosted by AT&T and DISH spanned across 4 labs in cooperation with several universities:

  • TIP Community Lab at Meta, Menlo Park CA
  • POWDER Lab and NSF PAWR SITE with the University of Utah
  • COSMOS Lab and NSF PAWR SITE with the Rutgers University, Columbia University, NYU Wireless
  • InterOperability Lab at the University of New Hampshire

Activities focused on demonstrations of use cases within the O-RAN Use Cases Detailed Specification version 6.0 & 7.0, as well as use cases that are currently in the process of being specified such as Energy Saving / Energy Efficiency. More than 20 unique O-RAN components were tested for conformance to O-RAN specifications.

The Proof-of-Concept approach also supported the evolution of testbeds across companies and research institutions, which is expected to accelerate the availability of next generation research platforms, consistent with the mission of the recently established nGRG within O-RAN.

In addition to the hosts and labs, participants included Analog Devices, Anritsu, Calnex Solutions, Cisco, Fujitsu, HCL, highstreet technologies, IP Infusion, ITRI, Juniper Networks, Keysight Technologies, META, NSF ARA: Living Wireless Lab, NSF PAWR: AERPAW, NSF PAWR: Colosseum, Rohde & Schwarz, VIAVI Solutions, VMware and Wind River.

In Europe, the O-RAN PlugFest Spring 2022 hosted by Telefonica took place at the European OTIC in Madrid.

Activities focused on testing of open Xhaul transport solutions, including data plane functional and performance testing, as well as synchronization. Testing scenarios were mimicking realistic deployments with diversity of technologies, protocols, and encapsulations, to obtain meaningful insights on the solutions under test. There were three setups with different transport equipment, two instrumentation vendors, and one transceiver manufacturer.

In addition to the host, participants included ADVA Optical Networking, Juniper Networks, Keysight Technologies, Precision Optical Transceivers, Ribbon and VIAVI Solutions.

In Asia, O-RAN PlugFest Spring 2022 hosted by Auray took place at the Auray OTIC and Security Lab.

Divided into 18 test cases, activities focused on verification and validation of applicability of tests in a lab environment, specifically for Open Fronthaul tests, end-to-end tests, and Denial of Service (DoS) and blind exploitation types of security tests.

Performed actions covered a dry run of the O-RAN Certification and Badging, verifying the related processes and procedures.

The PlugFest also included Open RAN Testing and Optimization for Industry IoT – smart scoring methodology for end-to-end service experience based on 3GPP 5G E2E KPIs.

In addition to the host, participants included Alpha Networks, Askey Computer, Calnex Solutions, Foxconn, Institute for Information Industry, Inventec, IP Infusion, ITRI, JPC connectivity, Keysight Technologies, Lions Technology, LITEON, MICAS, NKG, Pegatron, QCT, REIGN Technology, Rohde & Schwarz, Sageran, VIAVI Solutions and WNC.

The O-RAN ALLIANCE is preparing a web announcement and a Virtual Showcase to allow interested public to explore the O-RAN Global PlugFest Spring 2022 in detail – soon to be available at our website.

About O-RAN ALLIANCE

The O-RAN ALLIANCE is a world-wide community of more than 340 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.

For more information, please visit www.o-ran.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

O-RAN ALLIANCE PR Contact

Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye